Clinical trials: Atypical Depression
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Recurrent Major Depressive Disorder With Atypical Features
Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features
The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression.
- Trial name
- NCT00585585
- Testing
- betahistine dihydrochloride
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Cincinnati
Major Depressive Disorder With Psychotic Features
Study of Pharmacotherapy of Psychotic Depression
This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.
- Trial name
- STOP-PD (NCT00056472)
- Testing
- Olanzapine, Sertraline
- Where
- 4 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Weill Medical College of Cornell University
Postpartum Depressive Disorder
Quetiapine in Postpartum Depression
The purpose of the study is to evaluate the efficacy and tolerability of quetiapine in female patients with postpartum depressive disorder with psychotic symptoms
- Trial name
- NCT00681668
- Testing
- Quetiapine
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- AstraZeneca
Dysthymic Disorder, Depressive Disorder NOS
Duloxetine for Chronic Depression: a Double-blind Study
The investigators are studying a new antidepressant medicine, duloxetine, for the treatment of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by the FDA for the treatment of major…
- Trial name
- NCT00360724
- Testing
- Duloxetine (Cymbalta)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- New York State Psychiatric Institute